IRIS - Res&Arch Institutional Research Information System - Research & Archive

GAETANI, LORENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.403
AS - Asia 2.176
EU - Europa 1.584
SA - Sud America 346
Continente sconosciuto - Info sul continente non disponibili 150
AF - Africa 66
OC - Oceania 8
Totale 7.733
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.293
SG - Singapore 1.011
IT - Italia 456
CN - Cina 316
HK - Hong Kong 279
BR - Brasile 255
IE - Irlanda 223
RU - Federazione Russa 210
VN - Vietnam 140
DE - Germania 128
BD - Bangladesh 101
FR - Francia 100
GB - Regno Unito 80
KR - Corea 76
SE - Svezia 76
FI - Finlandia 71
CA - Canada 61
IN - India 54
NL - Olanda 39
JP - Giappone 28
RO - Romania 28
AR - Argentina 27
TR - Turchia 27
UA - Ucraina 24
PL - Polonia 23
IQ - Iraq 21
AT - Austria 20
ID - Indonesia 20
ZA - Sudafrica 20
BE - Belgio 19
CO - Colombia 19
CZ - Repubblica Ceca 18
MX - Messico 16
UZ - Uzbekistan 15
PK - Pakistan 14
SA - Arabia Saudita 13
EC - Ecuador 12
PH - Filippine 11
VE - Venezuela 11
ES - Italia 10
GR - Grecia 9
HR - Croazia 9
JM - Giamaica 8
MA - Marocco 8
NI - Nicaragua 7
PT - Portogallo 7
TN - Tunisia 7
CL - Cile 6
KZ - Kazakistan 6
LT - Lituania 6
PY - Paraguay 6
AE - Emirati Arabi Uniti 5
NZ - Nuova Zelanda 5
AZ - Azerbaigian 4
BB - Barbados 4
CH - Svizzera 4
EG - Egitto 4
KE - Kenya 4
SC - Seychelles 4
UY - Uruguay 4
BG - Bulgaria 3
CR - Costa Rica 3
DK - Danimarca 3
DZ - Algeria 3
ET - Etiopia 3
GE - Georgia 3
HN - Honduras 3
IR - Iran 3
JO - Giordania 3
KG - Kirghizistan 3
LB - Libano 3
MD - Moldavia 3
NP - Nepal 3
PA - Panama 3
TW - Taiwan 3
AL - Albania 2
BO - Bolivia 2
GM - Gambi 2
GY - Guiana 2
IS - Islanda 2
MY - Malesia 2
NO - Norvegia 2
OM - Oman 2
PE - Perù 2
SD - Sudan 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BY - Bielorussia 1
BZ - Belize 1
CM - Camerun 1
CY - Cipro 1
EE - Estonia 1
HT - Haiti 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 7.564
Salva come PNG Salva come JPEG
Città #
Singapore 749
San Jose 434
Ashburn 330
Hong Kong 268
Chandler 257
Dublin 222
Perugia 146
Santa Clara 127
Council Bluffs 124
Boardman 123
Los Angeles 97
Moscow 86
Beijing 78
Seoul 76
Munich 70
Lauterbourg 69
San Mateo 69
New York 66
Altamura 59
Dallas 56
Phoenix 45
Des Moines 43
Princeton 42
Medford 40
Piscataway 40
Andover 39
Lawrence 39
Ann Arbor 38
Ho Chi Minh City 38
Wilmington 37
Hanoi 36
Milan 35
The Dalles 35
Helsinki 31
Rome 30
Turku 26
Denver 25
São Paulo 25
Redmond 24
Tokyo 23
Boston 21
Chennai 21
Houston 21
Brooklyn 20
Amsterdam 19
Chicago 19
Montreal 18
Redwood City 18
Atlanta 17
Orem 17
Buffalo 16
London 16
Nuremberg 16
Stockholm 16
Frankfurt am Main 15
Vienna 15
Warsaw 15
Brussels 14
Falls Church 14
Charlotte 13
San Francisco 13
Brno 12
Carrboro 12
Johannesburg 12
Manchester 12
Rio de Janeiro 12
Seattle 11
Tashkent 11
Naples 10
Newark 10
Poplar 10
Riverbank 10
Timisoara 10
Columbus 9
Florence 9
Haiphong 9
North Bergen 9
Toronto 9
Hefei 8
Zagreb 8
Baghdad 7
Bogotá 7
Fairfield 7
Kingston 7
Lappeenranta 7
Managua 7
Mexico City 7
Belo Horizonte 6
Brescia 6
Bucharest 6
Da Nang 6
Falkenstein 6
Guangzhou 6
Lahore 6
Miami 6
New Delhi 6
Norwalk 6
Saint Petersburg 6
Secaucus 6
Turin 6
Totale 4.871
Salva come PNG Salva come JPEG
Nome #
CSF and blood biomarkers for Parkinson's disease 214
Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation 174
Synaptic plasticity and experimental autoimmune encephalomyelitis: implications for multiple sclerosis 157
Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis 150
Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis 149
Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis 140
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment 139
Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis 132
A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation 130
2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes 126
High performance liquid chromatography determination of L-glutamate, L-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer's disease 124
Visual pathway involvement in multiple sclerosis: Look straight in the eyes 123
Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms 119
A microbially produced AhR ligand promotes a Tph1-driven tolerogenic program in multiple sclerosis 117
Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency 117
Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis 116
CSF neurochemical profile and cognitive changes in Parkinson's disease with mild cognitive impairment 115
Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction 110
Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers 109
Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes 105
Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington's and Parkinson's disease 104
Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease 103
Cerebrospinal fluid and serum D-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease 102
α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward 102
Insights into the pathophysiology of psychiatric symptoms in central nervous system disorders: Implications for early and differential diagnosis 101
Synaptic dysfunction in multiple sclerosis: A red thread from inflammation to network disconnection 99
Retinopathy during interferon-β treatment for multiple sclerosis: case report and review of the literature 98
Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis 97
Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis 93
Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics 93
Does cerebrospinal fluid neurofilament light chain correlate with psychiatric symptoms severity in multiple sclerosis? 93
Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain 92
Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: Disease staging by NF-L, p-tau181, and GFAP 91
Molecular profiling in Parkinsonian syndromes: CSF biomarkers 91
Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay 90
Neurofilament light chain as a biomarker in neurological disorders 90
Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica 88
Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum 87
CSF synaptic biomarkers and cognitive impairment in multiple sclerosis 87
The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers. 87
The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI 87
Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease 87
High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline 84
Intrathecal B cell activation and memory impairment in multiple sclerosis 82
Impact of post-contrast MRI in the definition of active multiple sclerosis 82
CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective 82
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 82
Blood biomarkers may distinguish among dementia disorders 82
Author Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use 81
Finding a way to preserve mitochondria: New pathogenic pathways in experimental multiple sclerosis 81
Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias 80
CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease 80
Cerebrospinal fluid interferon-γ and development of depression in multiple sclerosis 78
Association between Neuropsychological Performance and CSF Profile in Subjective Cognitive Decline: Towards the Diagnosis of Preclinical AD 77
CSF neurosecretory proteins VGF and neuroserpin in patients with Alzheimer's and Lewy body diseases 77
Biomarker-Based Prediction of Parkinson Disease: Time for a Shift in Neurologists' Attitude Toward Neurodegenerative Diseases 76
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease 76
Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts 76
Serum neurofilament light chain as a preclinical marker of neurodegeneration 76
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment 76
Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer's disease 75
Clinical correlates of state and trait anxiety in multiple sclerosis 75
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers 75
Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion 74
Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation 73
The Immune Signature of CSF in Multiple Sclerosis with and without Oligoclonal Bands: A Machine Learning Approach to Proximity Extension Assay Analysis 72
Post-contrast MRI in multiple sclerosis: Towards a judicious use of gadolinium-based contrast agents 72
Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer’s disease biomarkers 71
A blood test for Alzheimer's disease: a step forward 70
LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes 68
Infliximab monotherapy for neuro-Behçet's disease: a case report 68
Lower urinary tract symptoms and urodynamic dysfunctions in clinically isolated syndromes suggestive of multiple sclerosis. 68
Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders 67
Blood-based biomarkers for Alzheimer’s disease: influence of kidney function 65
CSF and plasma Aβ42/40 across Alzheimer's disease continuum: comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions 63
Research advancement in fluid biomarkers for Parkinson's disease 61
Diagnostic value of kappa free light chain index in patients with primary progressive multiple sclerosis – a multicentre study 53
SARS-CoV-2 vaccines tolerability: A perspective by people with multiple sclerosis 51
Transcriptome analysis of the prefrontal cortex identifies inflammatory genes associated with cognitive impairment in a model of multiple sclerosis 50
Fluid biomarkers in multiple sclerosis: from current to future applications 50
Immune profiling unveils the systemic cytokine milieu associated with acute reversible encephalopathy with cytotoxic lesions of the corpus callosum (CLOCCs) 40
Hippocampal neuroplasticity and inflammation: Relevance for multiple sclerosis 40
A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders 38
Phosphorylated α-synuclein in CSF and plasma does not reflect synucleinopathy 34
Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer’s disease and Parkinson’s disease 26
Cerebrospinal fluid α-synuclein seed amplification assay positivity is associated with increased plasma neurofilament light chain in Alzheimer's disease 25
Reference proteins to improve Core 1 and Core 2 Alzheimer’s disease CSF and plasma biomarkers 22
Prognostic value of kappa free light chain index in patients with primary progressive multiple sclerosis 16
Italian intersocietal recommendations for restructuring the diagnostic-therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer’s disease 15
Totale 7.733
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.866
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.866
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022316 0 0 0 12 26 10 5 93 17 46 61 46
2022/2023858 45 184 15 68 62 104 4 38 302 1 26 9
2023/2024511 24 54 15 11 7 2 97 20 68 26 80 107
2024/20251.392 13 108 69 75 122 103 95 139 239 85 220 124
2025/20263.200 205 239 128 412 430 300 503 157 298 269 160 99
2026/20271.046 92 134 288 532 0 0 0 0 0 0 0 0
Totale 7.733